Accessibility statement

David Epstein
Honorary Visiting Research Fellow

Profile

Biography

David Epstein joined the team for economic evaluation of health technologies in 2002.

His research interests include:

  • Economic evaluation of health care technologies and mathematical programming for resource allocation

His current projects include:

  • The economic evaluation of adjuvant therapies for women with early breast cancer
  • The economic evaluation of a series of health care technologies on behalf of the Junta de Andalucia, Spain
  • Uncertainty and the value of information using stochastic mathematical programming

David gained an MSc in Health Economics from York in 2002 and a PhD in Economics from the University of Granada, Spain in 2010. He is a CIMA qualified accountant.

Research

Overview

  • Economic evaluation of health care technologies and mathematical programming for resource allocation

Research group(s)

Publications

Full publications list

2013

  • Epstein D, Mochón LG, Espín J, Soares MO. Use of multi-parameter evidence synthesis to assess the appropriateness of data and structure in decision models. Medical Decision Making 2013;doi:10.1177/0272989X13480130. Download from sagepub
  • Faria R, Bojke L, Epstein D, Corbacho B, Sculpher M, On the behalf of the REFLUX trial group. Cost-effectiveness of laparoscopic fundoplication versus continued medical management for the treatment of gastro-oesophageal reflux disease based on long-term follow-up of the REFLUX trial. British Journal of Surgery 2013;100(9):1205-1213.
  • Grant A, Boachie C, Cotton S, Faria R, Bojke L, Epstein D, Ramsay C, Corbacho B, Sculpher M, Krukowski Zh, Heading R, Campbell M. Clinical and economic evaluation of laparoscopic surgery compared with medical management for gastro-oesophageal reflux disease: 5-year follow-up of multicentre randomised trial (the REFLUX trial). Health Technology Assessment 2013;17(22).

2012

  • Yang H, Craig D, Epstein D, Bojke L, Light K, Bruce I, Sculpher M, Woolacott N. Golimumab for the treatment of psoriatic arthritis: A NICE Single Technology Appraisal. Pharmacoeconomics 2012;30:257-70.

2011

  • Bojke L, Epstein D, Craig D, Rodgers M, Woolacott N, Yang H, Sculpher M. Modelling the cost-effectiveness of biologic treatments for psoriatic arthritis. Rheumatology 2011;50:iv39-iv47.
  • Campbell HE, Epstein D, Bloomfield D, Griffin S, Manca A, Yarnold J, Bliss J, Johnson L, Earl H, Poole C, Hiller L, Dunn J, Hopwood P, Barrett-Lee P, Ellis P, Cameron D, Harris AL, Gray AM, Sculpher MJ. The cost-effectiveness of adjuvant chemotherapy for early breast cancer: a comparison of no chemotherapy and first, second, and third generation regimens for patients with differing prognoses. European Journal of Cancer 2011;Nov 47(17):2517-30. Download from Sciencedirect
  • Epstein D, Sutton A. Modelling correlated clinical outcomes in health technology appraisal. Value in Health 2011;14(6):793-99. Download from Value in Health
  • Rodgers M, Epstein D, Bojke L, Yang H, Craig D, Fonseca T, Myers L, Bruce I, Chalmers R, Bujkiewicz S, Lai M, Cooper N, Abrams K, Spiegelhalter D, Sutton A, Sculpher M, Woolacott N. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technol Assess 2011;15(10):1-329. Download from HTA
  • Rodgers M, Soares M, Epstein D, Yang H, Fox D, Eastwood A. Bevacizumab in combination with a taxane for the first-line treatment of HER2-negative metastatic breast cancer. Health Technology Assessment 2011;15:Suppl.1. Download from HTA

2010

  • Gohel MS, Epstein D, Davies AH. Cost-effectiveness of traditional and endovenous treatments for varicose veins. Br J Surg 2010;97(12):1815-23. Download from pubmed
  • McKenna C, Chalabi Z, Epstein D, Claxton K. Budgetary policies and available actions: a generalisation of decision rules for allocation and research decisions. Journal of Health Economics 2010; 29: 170–181. Download from Science Direct
  • The United Kingdom EVAR Trial Investigators. Endovascular versus open repair of abdominal aortic aneurysm. New England Journal of Medicine 2010;362:1863-71. Download from NEJM
  • The United Kingdom EVAR Trial Investigators. Endovascular repair of aortic aneurysm in patients physically ineligible for open repair. New England Journal of Medicine 2010;362:1872-80. Download from NEJM

     

2009

  • Burch J, Epstein D, Baba-Akbari Sari A, Weatherly H, Jayne D, Fox D, et al. Stapled haemorrhoidopexy for the treatment of haemorrhoids: a systematic review. Colorectal Disease. 2009;11:233-44.
  • Chambers D, Epstein D, Walker S, Fayter D, Paton F, Wright K, Michaels J, Thomas S, Sculpher M, Woolacott N. Endovascular stents for abdominal aortic aneurysms: a systematic review and economic model. Health Technology Assessment 2009;13(48):pp1-214.
  • Epstein D. Is EVAR worth the price difference? In: Greenhalgh R, editor. Vascular and endovascular controversies Update 31. London: Biba Medical; 2009.
  • Epstein D. Opportunity cost. In: Encyclopedia of medical decision making: Sage Publications; 2009.
  • Epstein D, Bojke L, Sculpher M & the REFLUX trial group. The cost-effectiveness of laparoscopic fundoplication versus medical management for gastro oesophageal reflux disease. British Medical Journal 2009;338:b2576.
  • Epstein D, Jimenez Rubio D, Smith PC, Suhrcke M. An economic framework for analysing the social determinants of health and health inequalities. Centre for Health Economics, University of York; CHE Research Paper 52 (PDF , 786kb)‌ 2009.
  • Epstein D, Jimenez Rubio D, Smith PC, Suhrcke M. Social determinants of health: an economic perspective. Health Economics 2009;18:495-502.

2008

  • Al-Ruzzeh S, Epstein D, George S, Bustami M, Wray J, Ilsley C, Sculpher M, Amrani M. Economic evaluation of coronary artery bypass grafting surgery with and without cardiopulmonary bypass: cost-effectiveness and quality-adjusted life years in a randomized controlled trial. Artificial Organs. 2008;32(11):891-7. Download from Wiley Inter Science
  • Burch J, Epstein D, Baba-Akbari A, Weatherly H, Fox D, Golder S, Jayne D, Drummond M, Woolacott N. Stapled haemorrhoidectomy (haemorrhoidopexy) for the treatment of haemorrhoids: a systematic review and economic evaluation. Health Technology Assessment 2008;12(8). Download from HTA
  • Chalabi Z, Epstein D, McKenna C, Claxton K. Uncertainty and value of information when allocating resources within and between healthcare programmes. European Journal of Operational Research. 2008;191(2):530-9. Download from Science Direct
  • Epstein DM, Garcia Mochon L. The accuracy of telemedicine compared with conventional methods in the diagnosis of malignant melanoma of the skin. Revista Espanola de Economia de la Salud. 2008;7:193-6.
  • Epstein D, Sculpher M, Clayton T, Henderson R, Pocock SJ, Buxton M, et al. Costs of an early intervention versus a conservative strategy in acute coronary syndrome. International Journal of Cardiology. 2008;127(2):240-6. Download from Science Direct
  • Epstein D, Sculpher M, Manca A, Michaels J, Thompson SG, Brown LC, et al. Modelling the long-term cost-effectiveness of endovascular or open repair for abdominal aortic aneurysm. British Journal of Surgery. 2008;95:183-90. 
  • Epstein D, Mason A, Manca A. The hospital costs of care for stroke in nine European countries. Health Economics. 2008;17 (S1):S21-S31. Download from Wiley Inter Science
  • Grant A, Wileman S, Ramsay C, Bojke L, Epstein D, Sculpher M, et al. The effectiveness and cost-effectiveness of minimal access surgery amongst people with gastro-oesophageal reflux disease - a UK collaborative study. The REFLUX trial. Health Technology Assessment. 2008;12(31):1-204.
  • Henriksson M, Epstein D, Palmer SJ, Sculpher MJ, Clayton TC, Pocock SJ, et al. The cost-effectiveness of an early interventional strategy in non-ST-elevation acute coronary syndrome based on the RITA 3 trial. Heart. 2008;94:717-23. Download from BMJ.com
  • McKenna C, Chalabi Z, Epstein D, Claxton K. Budgetary policies and available actions: a generalisation of decision rules for allocation and research decisions. Centre for Health Economics, University of York; CHE Research Paper 44 (PDF , 368kb)‌ , 2008.
  • Olry de Labry Lima A, Sordo del Castillo L, Garcia Mochon L, Epstein D, Bermudez C, Villegas R. Evaluacion economica de la prueba genetica de la poliposis adenomatosa familiar. Rev Esp Enfirm Dig. 2008;100(8):470-5.

2007

  • Epstein D, Chalabi Z, Claxton K, Sculpher M. Efficiency, equity and budgetary policies: informing decisions using mathematical programming. Medical Decision Making. 2007;27:128-37.
  • Epstein D. The health related quality of life of patients with acute coronary syndrome: a comparison of early intervention versus conservative management. Revista Espanola de Economia de la Salud. 2007;6:380-5.
  • Olry de Labry Lima A, Epstein D, Garcia Mochon L, et al. Comparacion de costes y supervivencia en pacientes intervenidos quirurgicamente de cancer colorrectal segun diferentes modelos organizativos. Rev Esp Enfirm Dig. 2007;99(11):643-7.

2006

  • Epstein D, Chalabi Z, Claxton K, Sculpher M. Mathematical programming for the optimal allocation of health care resources. Mathematical programming for the optimal allocation of health care resources (PDF , 540kb)‌
  • Epstein D, Mason A. Costs and prices for inpatient care in England: mirror twins or distant cousins? Health Care Management Science. 2006 August;9(3):233-42.
  • Manca A, Epstein D, Torgerson D, Klaber Moffett J, Coulton S, Farrin A, et al. Randomised trial of a brief physiotherapy intervention compared with usual physiotherapy for neck pain patients: a cost-effectiveness analysis. International Journal of Technology Assessment in Health Care. 2006;22(1):67-75.

2005

  • Hawkins N, Sculpher M, Epstein D. Cost-effectiveness analysis of treaments for chronic disease: using R to incorporate time dependency of treatment response. Medical Decision Making 2005;25:511-519.
  • Hawkins N, Epstein D, Drummond M, Wilby J, Kainth A, Chadwick DM, et al. Assessing the cost-effectiveness of new pharmaceuticals in epilepsy in adults: the results of a probabilistic decision model. Medical Decision Making 2005;25:493-510.
  • Wilby J, Kainth A, Hawkins N, Epstein D, McIntosh H, McDaid C, Mason A, Golder S, O'Meara S, Sculpher M, Drummond M, Forbes C. A rapid and systematic review of the clinical effectiveness, tolerability and cost effectiveness of newer drugs for epilepsy in adults. Health Technology Assessment 2005;9(15):1-172.

Recent presentations

 

Teaching

Other teaching

  • Course Tutor: Técnicas de modelización en evaluación económica de medicamentos y tecnologías sanitarias. Centre de Recerca en Economía y Salut (CRES), Universitat Pompeu Fabra, Barcelona

Contact details

David Epstein
Honorary Visiting Research Fellow
Centre for Health Economics